Literature DB >> 22336489

Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients.

Pit Jacob Voss1, Joel Joshi Oshero, Alice Kovalova-Müller, Egle Alina Veigel Merino, Sebastian Sauerbier, Jamil Al-Jamali, Juliana Lemound, Marc Christian Metzger, Rainer Schmelzeisen.   

Abstract

INTRODUCTION: Bisphosphonates are used to reduce skeletal related events in patients with bone consuming diseases such as osteoporosis and bone metastases. However recently there has been an increased awareness of bisphosphonate-associated necrosis of the jaws (BP-ONJ). Many authors propose conservative management in these cases but invariably the problem is not treated successfully allowing the bone defect to worsen. Recently there has been a move to treat this problem surgically. The aim of this retrospective study was to provide a surgical solution for patients suffering from BP-ONJ.
MATERIALS AND METHODS: All patients presenting with BP-ONJ were treated with bone debridement of the affected area and multilayer wound closure. The considered variables were: gender, age, underlying diagnosis, type of bisphosphonate (BP) used, duration of bisphosphonate use, route of administration, location of the osteonecrosis, clinical symptoms, association with dental treatment and surgical outcome.
RESULTS: Nineteen cases of a total of 21 demonstrated no recurrence of osteonecrosis during follow up (Mean 16 months - Range 12-24 months). One patient with a bilateral defect showed a dehiscence on one side and a small fistula on the contralateral side 6 weeks post-operatively and required revision surgery. Another patient developed a fistula after 4 weeks that was treated successfully with antibiotics and curettage. No patients had evidence of exposed bone, bland mucosa nor pain at the surgical site.
CONCLUSION: The technique described can be recommended for patients with BP-ONJ if a conservative treatment fails.
Copyright © 2012 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22336489     DOI: 10.1016/j.jcms.2012.01.005

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  21 in total

1.  Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells.

Authors:  Pit Jacob Voss; Akihiko Matsumoto; Esteban Alvarado; Rainer Schmelzeisen; Fabian Duttenhöfer; Philipp Poxleitner
Journal:  Odontology       Date:  2017-02-20       Impact factor: 2.634

2.  Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.

Authors:  Akihiko Matsumoto; Masanori Sasaki; Rainer Schmelzeisen; Yukiko Oyama; Yoshihide Mori; Pit Jacob Voss
Journal:  Clin Oral Investig       Date:  2016-02-29       Impact factor: 3.573

3.  The Prevention of Medication-related Osteonecrosis of the Jaw.

Authors:  Philipp Poxleitner; Monika Engelhardt; Rainer Schmelzeisen; Pit Voss
Journal:  Dtsch Arztebl Int       Date:  2017-02-03       Impact factor: 5.594

Review 4.  Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review.

Authors:  Larissa Fernandes Silva; Cláudia Curra; Marcelo Salles Munerato; Carlos Cesar Deantoni; Mariza Akemi Matsumoto; Camila Lopes Cardoso; Marcos Martins Curi
Journal:  Oral Maxillofac Surg       Date:  2015-12-11

5.  Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series.

Authors:  Adepitan A Owosho; Cherry L Estilo; Joseph M Huryn; SaeHee K Yom
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2016-07-13

6.  Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.

Authors:  Wei-Xiang Qi; Li-Na Tang; Ai-Na He; Yang Yao; Zan Shen
Journal:  Int J Clin Oncol       Date:  2013-04-20       Impact factor: 3.402

7.  Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol.

Authors:  Luca Ramaglia; Agostino Guida; Vincenzo Iorio-Siciliano; Alessandro Cuozzo; Andrea Blasi; Anton Sculean
Journal:  Clin Oral Investig       Date:  2018-01-13       Impact factor: 3.573

8.  Submental Perforator Flap for Soft-Tissue Reconstruction in Bisphosphonate-Related Osteonecrosis of the Jaws.

Authors:  Jose-Antonio García-de Marcos; Juan Rey-Biel
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2016-11-01

9.  Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient's Quality of Life: A Single-Center, 10-Year Experience from Southern Italy.

Authors:  Giacomo Oteri; Gianluca Trifirò; Matteo Peditto; Loredana Lo Presti; Ilaria Marcianò; Francesco Giorgianni; Janet Sultana; Antonia Marcianò
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

10.  Treatment of medication-related osteonecrosis of the jaws (MRONJ) with ultrasonic piezoelectric bone surgery. A case series of 20 treated sites.

Authors:  Cornelio Blus; Giulio Giannelli; Serge Szmukler-Moncler; Germano Orru
Journal:  Oral Maxillofac Surg       Date:  2016-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.